In this article, we will list the 5 Best Stocks That Recently Issued New Debt. Please visit 10 Best Stocks That Recently Issued New Debt if you’d like to see an extended list and how we came up with the list of best stocks that recently issued new debt.
5. TPG Inc. (NASDAQ:TPG)
TPG Inc. (NASDAQ:TPG) is one of the 10 best stocks that recently issued new debt.
On February 24, RBC Capital initiated coverage on TPG Inc. (NASDAQ:TPG). The firm assigned an Outperform rating to the stock and set a target price of $59. This leads to an upside potential of almost 49% at the current level.
RBC Capital noted that the recent selloff, driven by AI-related concerns, has created an attractive entry point. It added that TPG Inc. (NASDAQ:TPG) is expected to deliver stronger earnings growth compared to peers, supported by its proven private equity track record, which could act as a key advantage over time.
On February 24, Bank of America Securities reduced its price target on TPG Inc. (NASDAQ:TPG) from $77 to $72. The firm reiterated its Buy rating on the stock, which now yields an adjusted upside potential of more than 81% despite the downward revision.
The price target revision is part of Bank of America Securities’ broader updates. The firm is adjusting its EPS projections for several of its covered brokers, asset managers, and exchanges that have recently announced results.
TPG Inc. (NASDAQ:TPG) is an alternative asset manager that delivers investment management solutions. The company offers its services to a diverse group of clients that includes limited partners, separately managed accounts, funds, and other investment vehicles. It also provides services such as underwriting, placements, debt and equity capital solutions, and capital structuring advisory.
4. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 best stocks that recently issued new debt.
On March 11, Bank of America Securities reduced its price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from $97 to $85. The firm maintained a Buy rating on the stock, which now yields an adjusted upside of almost 54% despite the downward revision.
The firm stated that more cautious assumptions in the Voxzogo-franchise tail caused it to lower its outlook for the pro-forma entity. This comes prior to the conclusion of BioMarin’s acquisition of Amicus Therapeutics Inc. (NASDAQ:FOLD), scheduled during the second quarter.
Back on February 26, Whitney Ijem from Canaccord Genuity maintained her Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). The analyst also increased her price target from $98 to $104, leading to an upside potential of 88% at the prevailing level.
Ijem noted that the company’s fourth-quarter results included a slight top-line beat but were otherwise uneventful. This followed the announcement around the company’s acquisition of Amicus Therapeutics Inc. (NASDAQ:FOLD), and its investor conference that took place in January.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes targeted therapies for life-threatening medical conditions and rare genetic diseases. Some of its major products include VIMIZIM, VOXZOGO, NAGLAZYME, and ALDURAZYME. The company operates in more than 70 countries and currently has many drugs in the development stage.
3. ESAB Corp. (NYSE:ESAB)
ESAB Corp. (NYSE:ESAB) is one of the 10 best stocks that recently issued new debt.
On March 12, ESAB Corporation (NYSE:ESAB) announced that it has priced an offering of $1 billion aggregate principal amount of 5.625% senior notes due 2031. According to the industrial company, a portion of the purchase consideration for Eddyfi Holding and the related companies will be funded by the net proceeds.
The transaction is expected to close on March 26, subject to customary conditions, and some of the current and future domestic restricted subsidiaries of ESAB will provide the guarantee for the notes.
On February 23, JPMorgan increased the firm’s price target on ESAB Corp. (NYSE:ESAB) from $130 to $153. The firm maintained an Overweight rating on the stock, which yields an adjusted upside potential of more than 69% following the target revision.
The move comes on the back of updated estimates after the company’s fourth quarter report. It reflected a more positive view of the company’s performance going forward.
ESAB Corp. (NYSE:ESAB) is an industrial compounder that manufactures and supplies consumable products and equipment. These include cutting material, consumables & gas controlling solutions, and welding equipment. The company also offers software and digital solutions to enhance productivity and enable remote monitoring of welding operations.
2. Dave Inc. (NASDAQ:DAVE)
Dave Inc. (NASDAQ:DAVE) is one of the 10 best stocks that recently issued new debt.
On March 3, Joseph Vafi from Canaccord Genuity maintained his Buy rating on Dave Inc. (NASDAQ:DAVE). The analyst also increased the stock’s target price from $274 to $328, leading to a revised potential upside of almost 85%.
Vafi highlighted strong fourth-quarter and full-year 2025 performance for Dave Inc. (NASDAQ:DAVE), with the company exceeding its own guidance and outperforming the broader fintech sector. He also noted continued strength in user growth and pricing, with increases being absorbed without a meaningful impact on customer retention.
On March 3, Dave Inc. (NASDAQ:DAVE) reported fourth-quarter revenue of $163.7 million, higher than the consensus estimate of $162.28 million. For the third time in a row, the company has seen sales growth of over 60% year over year, signifying another successful quarter.
Founder and Chief Executive Officer Jason Wilk states that the company once again proved the strength of its growth algorithm with year-over-year increases of 36 percent in ARPU and 19 percent in the rate of acceleration of monthly transacting members. Wilk pointed out that the company’s 2.9 million members who transact each month represent only a small fraction of its overall 185 million-customer TAM.
Wilk also stated that the company believes it is still in the early stages of increasing incremental ARPU through enhancements in underwriting, ExtraCash features and pricing, and credit products. This gives the company’s management tremendous confidence in the company’s ability to continue delivering strong growth for many years to come.
Dave Inc. (NASDAQ:DAVE) offers a platform for financial services that includes budgeting, personal finance, and liquidity management. The platform tools notify members of upcoming transactions and recurring charges, based on individual bank account history. The company also offers job application solutions for temporary work.
1. Compass Inc. (NYSE:COMP)
Compass Inc. (NYSE:COMP) is one of the 10 best stocks that recently issued new debt.
On March 26, Benchmark Securities initiated its coverage on Compass Inc. (NYSE:COMP). The firm assigned a Buy rating to the stock and forecasted a price target of $14. This results in an upside potential of more than 92% at the current level.
On February 27, Compass Inc. (NYSE: COMP) released its fourth-quarter revenue figures. They came in at $1.7 billion, exceeding the high end of guidance and expanding by 23% year over year. Furthermore, the company announced a three-year strategic relationship with Rocket Redfin that will yield 1.2 million high-intent leads. From $16.7 million in the previous year, adjusted EBITDA increased by 249% to $58.3 million.
Robert Reffkin, the Founder, Chairman, and CEO, stated:
“We are pleased to have delivered a record fourth quarter revenue and adjusted EBITDA results, both exceeding the high end of our guidance.”
Reffkin unveiled the company’s new objective of achieving $400 million in net cost synergies over a three-year period, as well as its strategy to reach $250 million in cost synergies in the first year.
Compass Inc. (NYSE:COMP) is a technology-led residential real estate brokerage firm. It operates mobile apps and online platforms such as CIRE and Compass to deliver services such as cloud-based CRM, marketing, client service, and title & settlement services. It also enables consumer-grade user interfaces, insightful dashboards, and reporting.
While we acknowledge the potential of COMP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than COMP and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
